Acamprosate Completed Phase 4 Trials for Schizophrenic Disorders / Schizoaffective Disorders Treatment

IndicationsStatusPurposePhase
CompletedTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT00688324Biomarker Study of Acamprosate in Schizophrenia